The immunoassay market is segmented by technology into Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and RadioImmunoassay (RIA). ELISA holds the largest market share due to its wide range of applications and high sensitivity and specificity. CLIA is expected to witness significant growth in the forecast period due to technological advancements and increased demand for high-throughput testing. RIA is declining in popularity due to the use of safer and more advanced technologies.
Product
The market is segmented by product into reagents & kits and analyzers/instruments. Reagents & kits dominate the market due to their high demand for routine testing and ease of use. Analyzers/instruments segment is growing rapidly due to advancements in technology, automation, and increasing adoption by laboratories and healthcare facilities.
Specimen
Specimen segment includes blood, saliva, and urine. Blood specimen holds the largest market share due to its high accuracy and reliability in diagnostics. Saliva and urine specimens are gaining popularity due to their non-invasiveness and ease of collection, especially in point-of-care testing and home diagnostics.
Application
The market is segmented by application into oncology and cardiology. Oncology holds the largest market share due to the increasing prevalence of cancer and the demand for early detection and personalized medicine. Cardiology segment is growing steadily due to the rising incidence of cardiovascular diseases and the need for accurate and timely diagnosis and monitoring.
End-use
The market is segmented by end-use into hospitals & clinics and diagnostic labs. Hospitals & clinics hold the largest market share due to the high patient footfall and the availability of advanced diagnostic facilities. Diagnostic labs are witnessing significant growth due to the increasing outsourcing of diagnostic services and the trend towards centralized testing facilities.